From DNA to actionable result. Right now.

We believe that the greatest opportunity for breakthrough medical discoveries lives in the space where human science and computer science meets.

By combining scalable tech and unique algorithms to power Hyrax’s fully automated DNA sequence analysis platform, Exatype, Hyrax Biosciences delivers detailed and accurate drug resistance genotype reports, without the need for human intervention or the threat of human error.

1

Quality Control

Next-generation sequencing reads are trimmed of low-quality bases, and short or otherwise inferior reads are discarded.

2

Reference Mapping

Examap, a novel, codon-aware reference mapping tool, uses an assembly-free approach to map sequence reads to one or more reference sequences while considering both sequencing error and true diversity.

3

Mutation Calling

Mutations are called in each individual read. The Examap algorithm allows mutations to be called with >99% per-read accuracy.

4

Tailored Reporting

Relevant genes and mutations, at various prevalence levels, are reported and, if relevant, analysed using gold-standard drug-resistance testing algorithms.

Exatype, our flagship genotyping tool, is used globally for SARS-CoV-2 genotyping and HIV drug-resistance testing and can be extended to any organism. Contact us to adapt Exatype to your use case.

SARS-CoV-2 NGS analysis

The Exatype NGS SARS-CoV-2 solution supports the Illumina and Ion Torrent sequencing platforms.

Go to our NGS SARS-CoV-2 platform

HIV NGS analysis

The Exatype NGS HIV solution supports the Illumina and Ion Torrent sequencing platforms.

Go to our NGS HIV platform

HIV Sanger analysis

The Exatype Sanger HIV, solution supports any sequencing by capillary electrophoresis (CE), e.g. the Applied Biosystems 3730 and 3500 Series Genetic Analyzers.

Go to our Sanger HIV platform
info@hyraxbio.com